DK1273288T3 - Lægemiddelsammensætning indeholdende rapamycinderivater - Google Patents

Lægemiddelsammensætning indeholdende rapamycinderivater

Info

Publication number
DK1273288T3
DK1273288T3 DK02022256T DK02022256T DK1273288T3 DK 1273288 T3 DK1273288 T3 DK 1273288T3 DK 02022256 T DK02022256 T DK 02022256T DK 02022256 T DK02022256 T DK 02022256T DK 1273288 T3 DK1273288 T3 DK 1273288T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
composition containing
phosphatidylglycerol
sub
salt
Prior art date
Application number
DK02022256T
Other languages
Danish (da)
English (en)
Inventor
Harry Tiemessen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1273288T3 publication Critical patent/DK1273288T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
DK02022256T 1996-01-19 1997-01-20 Lægemiddelsammensætning indeholdende rapamycinderivater DK1273288T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9601120.0A GB9601120D0 (en) 1996-01-19 1996-01-19 Organic compounds
EP97901563A EP0874621B1 (de) 1996-01-19 1997-01-20 [3'-DESOXY-3-OXO-MeBmt]1-[Val]2-CICLOSPORIN ENTHALTENDE ARZNEIMITTELEMULSION

Publications (1)

Publication Number Publication Date
DK1273288T3 true DK1273288T3 (da) 2005-11-21

Family

ID=10787276

Family Applications (4)

Application Number Title Priority Date Filing Date
DK02022257T DK1273289T3 (da) 1996-01-19 1997-01-20 Farmaceutiske sammensætninger indeholdende ascomycinderivater
DK05018663.4T DK1679064T3 (da) 1996-01-19 1997-01-20 Farmaceutiske sammensætninger indeholdende rapamycinderivater
DK97901563T DK0874621T3 (da) 1996-01-19 1997-01-20 Lægemiddelemulsion indeholdende [3'-desoxy-3-oxy-MeBmt]1-[Val]2-ciclosporin
DK02022256T DK1273288T3 (da) 1996-01-19 1997-01-20 Lægemiddelsammensætning indeholdende rapamycinderivater

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK02022257T DK1273289T3 (da) 1996-01-19 1997-01-20 Farmaceutiske sammensætninger indeholdende ascomycinderivater
DK05018663.4T DK1679064T3 (da) 1996-01-19 1997-01-20 Farmaceutiske sammensætninger indeholdende rapamycinderivater
DK97901563T DK0874621T3 (da) 1996-01-19 1997-01-20 Lægemiddelemulsion indeholdende [3'-desoxy-3-oxy-MeBmt]1-[Val]2-ciclosporin

Country Status (14)

Country Link
US (2) US6239102B1 (de)
EP (4) EP1679064B1 (de)
JP (2) JP4077386B2 (de)
KR (1) KR100485146B1 (de)
AT (4) ATE239449T1 (de)
AU (1) AU1543497A (de)
CA (2) CA2678707A1 (de)
DE (3) DE69734742T2 (de)
DK (4) DK1273289T3 (de)
ES (4) ES2253483T3 (de)
GB (1) GB9601120D0 (de)
HK (3) HK1054183B (de)
PT (2) PT1679064E (de)
WO (1) WO1997025977A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660858A (en) * 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
PT1208847E (pt) 1996-07-30 2007-07-24 Novartis Ag Composições farmacêuticas para o tratamento da rejeição de transplantes, doenças autoimunes ou inflamatórias compreendendo ciclosporina a e 40-0-(2-hidroxietil)-rapamicina
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
JP4761093B2 (ja) 1997-12-10 2011-08-31 シクロスポリン セラポイティクス リミテッド オメガ−３脂肪酸油を含む医薬組成物
DE19810655A1 (de) * 1998-03-12 1999-09-16 Univ Eberhard Karls Arzneimittel mit einem Gehalt an Ciclosporin
AR018376A1 (es) 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
US7265150B1 (en) * 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
IL146162A0 (en) * 1999-04-30 2002-07-25 R Tech Ueno Ltd Macrolide compounds for the treatment of dry eye
EP1980263A1 (de) 1999-05-10 2008-10-15 Novartis AG Kombinationen von immunsuppressiven Mitteln zur Behandlung bzw. Prävention von Transplantatabstoßungen
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
HUP0600031A3 (en) 2000-10-31 2012-02-28 Pharma Mar Kahalalide formulations and their use
SI2762140T1 (sl) 2001-02-19 2017-07-31 Novartis Ag Zdravljenje trdnih možganskih tumorjev z derivatom rapamicina
US20050019372A1 (en) * 2001-07-10 2005-01-27 Barbara E Corkey Modified-fat nutritional products useful preventing or treating obesity
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
PT1436321E (pt) 2001-10-19 2006-10-31 Isotechnika Inc Sintese de analogos de ciclosporina
BR0316279A (pt) * 2002-11-15 2005-10-11 Novartis Ag Compostos orgânicos
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
WO2006135415A2 (en) * 2004-09-08 2006-12-21 University Of Florida Research Foundation, Inc. Micelles and nanoemulsions for preventative and reactive treatment of atherosclerosis
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP1848431B1 (de) * 2005-02-09 2016-02-03 Santen Pharmaceutical Co., Ltd. Flüssige formulierungen zur behandlung von erkrankungen oder leiden
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
EP2086602A2 (de) * 2006-11-20 2009-08-12 Lutonix, Inc. Wirkstofffreisetzende beschichtungen für medizinische vorrichtungen
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
WO2008082979A2 (en) * 2006-12-29 2008-07-10 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
WO2008082982A1 (en) 2006-12-29 2008-07-10 Abbott Laboratories Improved assay for immunosuppressant drugs
US7914999B2 (en) * 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
EP2118657B1 (de) * 2006-12-29 2014-05-21 Abbott Laboratories Nichtdenaturierendes lysereagens zur verwendung mit einem capture-in-solution-immunoassay
FR2911069B1 (fr) * 2007-01-09 2009-04-03 Physica Pharma Soc Par Actions Composition pharmaceutique parenterale et son procede de preparation
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
JP5753784B2 (ja) * 2008-10-10 2015-07-22 ダラ・バイオサイエンシズ，インコーポレイテッド スピカマイシン誘導体を用いて疼痛を治療又は予防する方法
EP2682106A1 (de) 2012-07-03 2014-01-08 Phares Pharmaceutical Research N.V. Verfahren zum Auflösen biologisch aktiver Verbindungen
ES2797376T3 (es) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
EP3532067B1 (de) 2016-10-28 2022-05-04 Les Laboratoires Servier Liposomale formulierung zur krebsbehandlung
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
KR102003183B1 (ko) 2019-02-27 2019-07-24 배영진 안면마스크

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE296122C (de) *
US4707470A (en) 1985-05-17 1987-11-17 Smithkline Beckman Corporation Polyene antibiotic emulsion formulation
CA1323306C (en) 1987-03-05 1993-10-19 Mircea C. Popescu Pharmacological agent-lipid solution preparation
EP0296122B1 (de) 1987-06-17 1993-09-29 Sandoz Ag Cyclosporine und deren Benutzung als Arzneimittel
JP2688235B2 (ja) 1987-09-07 1997-12-08 帝人株式会社 医薬物質含有脂肪乳剤の用時調製型キットおよび医薬物質含有脂肪乳剤の調製方法
IL88076A (en) 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
EP0356399A3 (de) * 1988-08-26 1991-03-20 Sandoz Ag Substituierte 4-Azatricyclo (22.3.1.04.9) octacos-18-en-Derivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
DD295766A5 (de) * 1988-10-10 1991-11-14 Arzneimittelwerk Dresden Gmbh,De Verfahren zur herstellung galenischer arzneiformen von ciclosporinen
JP2502719B2 (ja) 1988-12-28 1996-05-29 集合住宅用新材料・機器システム開発技術研究組合 冷暖給湯ヒ―トポンプシステム
DK0406791T3 (da) 1989-07-05 1995-03-27 Fujisawa Pharmaceutical Co Vandigt flydende præparat til ekstern anvendelse
JPH03147892A (ja) 1989-11-06 1991-06-24 Mitsubishi Rayon Co Ltd 昇華性分散染料易染性樹脂組成物
EP0427680B1 (de) * 1989-11-09 1995-08-23 Sandoz Ltd. Heteroatome enthaltende tricyclische Verbindungen
US5352671A (en) * 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
JPH04253907A (ja) * 1990-05-23 1992-09-09 Green Cross Corp:The 静脈注射用免疫抑制剤
IE65341B1 (en) 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
MX9201782A (es) * 1991-04-19 1992-10-01 Sandoz Ag Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5457111A (en) * 1991-09-05 1995-10-10 Abbott Laboratories Macrocyclic immunomodulators
DK0658344T3 (da) 1991-10-31 2000-04-17 Fujisawa Pharmaceutical Co Liposompræparat indeholdende tricyklisk forbindelse
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
DE59310166D1 (de) 1992-05-18 2001-05-31 Ciclomulsion Ag Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung
ES2168271T3 (es) 1992-09-25 2002-06-16 Novartis Ag Composiciones farmaceuticas que contienen ciclosporinas.
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JPH06183970A (ja) * 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd 医薬用組成物
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
GB2278780B (en) 1993-05-27 1998-10-14 Sandoz Ltd Macrolide formulations
AU688782B2 (en) * 1993-09-30 1998-03-19 Wyeth Rapamycin formulations for oral administration
FI100692B (fi) * 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
ATE214593T1 (de) * 1994-10-26 2002-04-15 Novartis Erfind Verwalt Gmbh Verwendung eines ungesättigten fettalkohols

Also Published As

Publication number Publication date
ES2253483T3 (es) 2006-06-01
ATE239449T1 (de) 2003-05-15
ES2199338T3 (es) 2004-02-16
ATE310504T1 (de) 2005-12-15
JP2007246543A (ja) 2007-09-27
HK1053973A1 (en) 2003-11-14
ES2247245T3 (es) 2006-03-01
US6239102B1 (en) 2001-05-29
DE69721729D1 (de) 2003-06-12
ES2365734T3 (es) 2011-10-10
JP2004107350A (ja) 2004-04-08
EP0874621A1 (de) 1998-11-04
EP1273289A1 (de) 2003-01-08
CA2240339C (en) 2010-11-16
DK1679064T3 (da) 2011-09-12
EP1679064A2 (de) 2006-07-12
GB9601120D0 (en) 1996-03-20
EP1273288A1 (de) 2003-01-08
WO1997025977A1 (en) 1997-07-24
EP1273289B1 (de) 2005-11-23
AU1543497A (en) 1997-08-11
EP0874621B1 (de) 2003-05-07
DE69734253D1 (de) 2006-02-02
USRE42014E1 (en) 2010-12-28
JP3763581B2 (ja) 2006-04-05
DE69734742D1 (de) 2005-12-29
HK1015277A1 (en) 1999-10-15
KR19990076603A (ko) 1999-10-15
HK1053973B (zh) 2006-09-29
HK1054183B (zh) 2006-07-28
DK0874621T3 (da) 2003-09-01
ATE510532T1 (de) 2011-06-15
ATE304842T1 (de) 2005-10-15
JP2000503655A (ja) 2000-03-28
EP1679064B1 (de) 2011-05-25
DE69734742T2 (de) 2006-07-27
DE69721729T2 (de) 2003-12-11
HK1054183A1 (en) 2003-11-21
EP1679064A3 (de) 2009-10-07
DE69734253T2 (de) 2006-07-06
PT874621E (pt) 2003-09-30
JP4077386B2 (ja) 2008-04-16
DK1273289T3 (da) 2006-03-20
PT1679064E (pt) 2011-07-25
EP1273288B1 (de) 2005-09-21
CA2678707A1 (en) 1997-07-24
CA2240339A1 (en) 1997-07-24
KR100485146B1 (ko) 2005-10-12

Similar Documents

Publication Publication Date Title
DK1273288T3 (da) Lægemiddelsammensætning indeholdende rapamycinderivater
US5059593A (en) Pour-on formulations which are active against ticks
KR950007859A (ko) 경구 투여용 라파마이신 제형
KR970706021A (ko) N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형제제(MEDICINAL ADJUVANTS CONSISTIONG OF AN N-SUBSTITUED-o-TOLUIDING DERIVANTIVE, AND PERCUTANEOUSLY ABSORBALE PREPARATIONS COMPRISING THE ADJUVANTS)
JPS6251932B2 (de)
HU9202404D0 (en) A stable preparative suitable for parentheral application
US4594357A (en) Depot antiinflammatory agents
KR940701251A (ko) 콜레스테롤-강하 토코페롤 동족체
KR930703251A (ko) 에어로졸 제제
SU1573021A1 (ru) 14 @ -Окси-7,8-метилендиоксиаллобербан, обладающий антидепрессивной активностью
US5034420A (en) Compositions and method for stabilization of anthralin comprising the addition of an oil soluble antioxidant and an anionic surfactant
ATE23150T1 (de) Aminoethoxybenzylalkohol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
JPS5655397A (en) Aminobenzoic acid ester derivative, and physiologically active agent containing said derivative
KR880013874A (ko) 카르복실산 에스테르, 그의 제조방법 및 그것을 유효 성분으로 함유하는 살충제
PT84635A (en) Process for the preparation of stable injectable compositions containing 4-amino-5-chloro-n-]2-(diethylamino) ethyl"-2-](substituted) alkoxy" benzamide antiemetic agents
SI8712284B (sl) Pripravki za nazalno uporabo in postopki za njihovo pridobivanje